Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Apnimed, Inc.APMD · Entity 4910 | Director | July 30, 2026 | August 03, 2026 |
| Harmony Biosciences Holdings, Inc.HRMY · Entity 4381 | Director | May 14, 2026 | May 18, 2026 |
| Nabriva Therapeutics Legacy plcNBRV · Entity 174291 | Chief Financial Officer | June 23, 2017 | June 28, 2017 |
| Nabriva Therapeutics plcNBRV · Entity 111497 | Chief Financial Officer | February 28, 2021 | March 02, 2021 |
| Schrodinger, Inc.SDGR · Entity 4667 | Director | June 22, 2026 | June 23, 2026 |
| iBio, Inc.IBIO · Entity 6906 | Director | November 20, 2025 | November 24, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Apnimed, Inc.
Report date July 30, 2026 · Filed August 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.50 · Expires 2034-12-12 | Direct | 0 |
Reported balance
After 2026-08-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-03 · Disposition to issuer · Disposed 51,890 · Balance 0 F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock. F2: 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after October 15, 2024, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.50 · Expires 2034-12-12 | Direct | 51,890 |
Reported balance
After 2026-08-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-03 · Grant · Acquired 51,890 · Balance 51,890 F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock. F2: 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after October 15, 2024, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.15 · Expires 2036-07-07 | Direct | 0 |
Reported balance
After 2026-08-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-03 · Disposition to issuer · Disposed 44,477 · Balance 0 F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock. F3: 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after July 7, 2026, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.15 · Expires 2036-07-07 | Direct | 44,477 |
Reported balance
After 2026-08-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-08-03 · Grant · Acquired 44,477 · Balance 44,477 F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock. F3: 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after July 7, 2026, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2036-07-29 | Direct | 44,477 |
Reported balance
After 2026-07-30 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-07-30 · Grant · Acquired 44,477 · Balance 44,477 F4: The shares subject to such option vest and become exercisable in substantially equal monthly installments for a period of 36 months after July 30, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2036-07-29 | Direct | 0 |
Reported balance
After 2026-08-03 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-08-03 · Disposition to issuer · Disposed 44,477 · Balance 0 F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock. F4: The shares subject to such option vest and become exercisable in substantially equal monthly installments for a period of 36 months after July 30, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2036-07-29 | Direct | 44,477 |
Reported balance
After 2026-08-03 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-08-03 · Grant · Acquired 44,477 · Balance 44,477 F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock. F4: The shares subject to such option vest and become exercisable in substantially equal monthly installments for a period of 36 months after July 30, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock.
F2: 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after October 15, 2024, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
F3: 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after July 7, 2026, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
F4: The shares subject to such option vest and become exercisable in substantially equal monthly installments for a period of 36 months after July 30, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date
Harmony Biosciences Holdings, Inc.
Report date May 14, 2026 · Filed May 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $30.76 · Expires 2036-05-14 | Direct | 21,872 |
Reported balance
After 2026-05-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-14 · Grant · Acquired 21,872 · Balance 21,872 F1: The stock option shall vest in full on the earlier to occur of (i) May 14, 2027 and (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option shall vest in full on the earlier to occur of (i) May 14, 2027 and (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date.
Nabriva Therapeutics Legacy plc
Report date June 23, 2017 · Filed June 28, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 2,200 |
Reported balance
After 2017-06-23 transaction · row 1
1 source rowRow 1 · 2017-06-23 · Other · Acquired 2,200 · Balance 2,200 F1: Reflects the beneficial ownership of the reporting person following the succession pursuant to Rule 12g-3(a) of the Securities Exchange Act of 1934, as amended, of Nabriva Therapeutics plc to Nabriva Therapeutics AG. The succession occurred following the conclusion, on June 23, 2017, of a tender offer related to the exchange of American depositary shares and common shares of Nabriva Therapeutics AG for ordinary shares of Nabriva Therapeutics plc. |
| Stock OptionSEC Table II · derivative / convertible security · Expires 2026-05-30 | Direct | 88,800 |
Reported balance
After 2017-06-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-06-23 · Other · Acquired 88,800 · Balance 88,800 F2: The exercise price is 6.50 Euro. F1: Reflects the beneficial ownership of the reporting person following the succession pursuant to Rule 12g-3(a) of the Securities Exchange Act of 1934, as amended, of Nabriva Therapeutics plc to Nabriva Therapeutics AG. The succession occurred following the conclusion, on June 23, 2017, of a tender offer related to the exchange of American depositary shares and common shares of Nabriva Therapeutics AG for ordinary shares of Nabriva Therapeutics plc. F3: This option was granted on May 31, 2016. Vesting began on May 31, 2016 and ends on May 31, 2020. Twenty-five percent (25%) of the option will vest on May 31, 2017, and the remaining seventy-five percent (75%) vests on a monthly pro-rata basis over the remaining vesting period. |
| Stock OptionSEC Table II · derivative / convertible security · Expires 2027-02-06 | Direct | 113,000 |
Reported balance
After 2017-06-23 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-06-23 · Other · Acquired 113,000 · Balance 113,000 F4: The exercise price is 7.963 Euro. F1: Reflects the beneficial ownership of the reporting person following the succession pursuant to Rule 12g-3(a) of the Securities Exchange Act of 1934, as amended, of Nabriva Therapeutics plc to Nabriva Therapeutics AG. The succession occurred following the conclusion, on June 23, 2017, of a tender offer related to the exchange of American depositary shares and common shares of Nabriva Therapeutics AG for ordinary shares of Nabriva Therapeutics plc. F5: This option was granted on February 7, 2017. Vesting began on February 28, 2017 and will end on February 28, 2021. Twenty-five percent (25%) of the option will vest on February 28, 2018, and the remaining seventy-five percent (75%) will vest on a monthly pro-rata basis over the remaining vesting period. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the beneficial ownership of the reporting person following the succession pursuant to Rule 12g-3(a) of the Securities Exchange Act of 1934, as amended, of Nabriva Therapeutics plc to Nabriva Therapeutics AG. The succession occurred following the conclusion, on June 23, 2017, of a tender offer related to the exchange of American depositary shares and common shares of Nabriva Therapeutics AG for ordinary shares of Nabriva Therapeutics plc.
F2: The exercise price is 6.50 Euro.
F3: This option was granted on May 31, 2016. Vesting began on May 31, 2016 and ends on May 31, 2020. Twenty-five percent (25%) of the option will vest on May 31, 2017, and the remaining seventy-five percent (75%) vests on a monthly pro-rata basis over the remaining vesting period.
F4: The exercise price is 7.963 Euro.
F5: This option was granted on February 7, 2017. Vesting began on February 28, 2017 and will end on February 28, 2021. Twenty-five percent (25%) of the option will vest on February 28, 2018, and the remaining seventy-five percent (75%) will vest on a monthly pro-rata basis over the remaining vesting period.
Nabriva Therapeutics plc
Report date February 28, 2021 · Filed March 02, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 20,472 |
Reported balance
After 2021-02-28 transaction · row 1
1 source rowRow 1 · 2021-02-28 · Tax withholding · Disposed 31 · Balance 20,472 F1: These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units. |
Filing footnotes · ownership attribution and instrument terms
F1: These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units.
Schrodinger, Inc.
Report date June 22, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 25,388 |
Reported balance
After 2026-06-22 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-22 · Grant · Acquired 8,141 · Balance 25,388 F1: Grant of restricted stock units ("RSUs") under the Issuer's 2022 Equity Incentive Plan, as amended. Each RSU represents a contingent right to receive one share of common stock of the Issuer. The RSUs were granted on June 22, 2026 and shall vest on the twelve-month anniversary of the date of grant of the award (or, if earlier, the date of the next annual meeting of stockholders following the date of grant of the award), subject to continued service. F2: Includes 8,141 unvested RSUs. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.23 · Expires 2036-06-22 | Direct | 13,313 |
Reported balance
After 2026-06-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-22 · Grant · Acquired 13,313 · Balance 13,313 F3: The option was granted on June 22, 2026 under the Issuer's 2022 Equity Incentive Plan, as amended. The award shall vest on the twelve-month anniversary of the date of grant of the award (or, if earlier, the date of the next annual meeting of stockholders following the date of grant of the award), subject to continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted stock units ("RSUs") under the Issuer's 2022 Equity Incentive Plan, as amended. Each RSU represents a contingent right to receive one share of common stock of the Issuer. The RSUs were granted on June 22, 2026 and shall vest on the twelve-month anniversary of the date of grant of the award (or, if earlier, the date of the next annual meeting of stockholders following the date of grant of the award), subject to continued service.
F2: Includes 8,141 unvested RSUs.
F3: The option was granted on June 22, 2026 under the Issuer's 2022 Equity Incentive Plan, as amended. The award shall vest on the twelve-month anniversary of the date of grant of the award (or, if earlier, the date of the next annual meeting of stockholders following the date of grant of the award), subject to continued service.
iBio, Inc.
Report date November 20, 2025 · Filed November 24, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.00 · Expires 2035-11-19 | Direct | 13,500 |
Reported balance
After 2025-11-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-11-20 · Grant · Acquired 13,500 · Balance 13,500 F1: These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant. |
Filing footnotes · ownership attribution and instrument terms
F1: These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 10, 2020 Filed Feb 10, 2020 21:05 UTC | Schrodinger, Inc. SDGR · Entity 4667 | GrantStock Option (right to buy) · Derivative | 12,909 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0000899243-20-003791 · doc4.xml · derivative · entry 1 Sender Gary · CIK 0001659085 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,909 Underlying: Common Stock · 12,909 shares Expires 2030-02-04 F1 · derivative.exercise_date: The option was granted on February 5, 2020. The commencement of vesting was contingent upon the closing of the Issuer's initial public offering, which occurred on February 10, 2020. The shares underlying the option are scheduled to vest in full on February 5, 2021. Read SEC document |
| February 06, 2020 Filed Feb 10, 2020 20:29 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | GrantStock Options · Derivative | 210,000 | $0.00 Strike: $1.35 | $0.00 |
DisclosureSEC source: 0001104659-20-015174 · a4.xml · derivative · entry 2 Sender Gary · CIK 0001659085 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,000 Underlying: Ordinary Shares · 210,000 shares Expires 2030-02-05 F2 · date: The option was granted on February 6, 2020, subject to shareholder approval; provided, that if such shareholder approval is not obtained, the option will remain outstanding and convert into a cash-settled share appreciation right. F3 · derivative.exercise_date: The option will vest over a four-year period beginning on February 6, 2020. Twenty-five percent (25%) of the option will vest on the one (1) year anniversary of the date of grant, and the remaining seventy-five percent (75%) of the option will vest on a monthly pro-rata basis over the remaining vesting period. Read SEC document |
| February 06, 2020 Filed Feb 10, 2020 20:29 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | GrantOrdinary Shares | 105,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-015174 · a4.xml · nonDerivative · entry 1 Sender Gary · CIK 0001659085 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,669 F1 · balance_after: The reported transaction involved the reporting person's receipt of a grant of 105,000 restricted stock units. The total reported in Column 5 includes the 105,000 newly awarded restricted stock units. Read SEC document |
| January 31, 2020 Filed Feb 4, 2020 20:56 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | Tax withholdingOrdinary Shares | 4,295 | $1.35 | $5,798.25 |
DisclosureSEC source: 0001104659-20-010900 · a4.xml · nonDerivative · entry 2 Sender Gary · CIK 0001659085 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,669 Read SEC document |
| August 21, 2019 Filed Aug 21, 2019 21:22 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | Tax withholdingOrdinary Shares | 3,390 | $2.08 | $7,051.20 |
DisclosureSEC source: 0001104659-19-046858 · a4.xml · nonDerivative · entry 2 Sender Gary · CIK 0001659085 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,214 Read SEC document |
| August 21, 2019 Filed Aug 26, 2019 21:35 UTC Amendment | Nabriva Therapeutics plc NBRV · Entity 111497 | SaleOrdinary Shares | 3,390 | $2.08 | $7,051.20 |
DisclosureSEC source: 0001104659-19-047348 · a4a.xml · nonDerivative · entry 1 Sender Gary · CIK 0001659085 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,214 F1 · kind: This amendment is being filed solely to correct the transaction code from "F" to "S" for the sale of ordinary shares to satisfy tax withholding obligations in connection with the transaction reported in the Form 4 filed by the reporting person on August 21, 2019. Read SEC document |
| August 19, 2019 Filed Aug 21, 2019 21:22 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | Exercise / conversionRestricted Share Units · Derivative | 11,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-046858 · a4.xml · derivative · entry 3 Sender Gary · CIK 0001659085 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,250 Underlying: Ordinary Shares · 11,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted share units convert into ordinary shares on a one-for-one basis upon vesting of the units. F2 · derivative.exercise_date: On January 31, 2018, Nabriva Therapeutics plc (the "Issuer") granted the reporting person 22,500 restricted share units ("RSUs"). Fifty percent (50%) of the RSUs vested on August 19, 2019 upon certifcation by the board of directors of the Issuer of the receipt by the Issuer of approval of a new drug application by the U.S. Food and Drug Administration for lefamulin (the "Performance Condition"), and the remaining fifty percent (50%) of the RSUs will vest on the one (1) year anniversary of the Performance Condition. F2 · derivative.expiration_date: On January 31, 2018, Nabriva Therapeutics plc (the "Issuer") granted the reporting person 22,500 restricted share units ("RSUs"). Fifty percent (50%) of the RSUs vested on August 19, 2019 upon certifcation by the board of directors of the Issuer of the receipt by the Issuer of approval of a new drug application by the U.S. Food and Drug Administration for lefamulin (the "Performance Condition"), and the remaining fifty percent (50%) of the RSUs will vest on the one (1) year anniversary of the Performance Condition. Read SEC document |
| August 19, 2019 Filed Aug 21, 2019 21:22 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | Exercise / conversionOrdinary Shares | 11,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-046858 · a4.xml · nonDerivative · entry 1 Sender Gary · CIK 0001659085 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,604 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The restricted share units convert into ordinary shares on a one-for-one basis upon vesting of the units. Read SEC document |
| January 31, 2019 Filed Feb 4, 2019 16:07 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | GrantRestricted Stock Units · Derivative | 52,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-005522 · a4.xml · derivative · entry 2 Sender Gary · CIK 0001659085 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,500 Underlying: Ordinary Shares · 52,500 shares Expires 2023-01-31 F3 · derivative.exercise_price: The restricted stock unit shall convert into ordinary shares on a one-for-one basis upom vesting of the units. F4 · derivative.exercise_date: The restricted stock unit award was granted on January 31, 2019. Vesting began on January 31, 2019 and ends on January 31, 2023. Twenty-five percent (25%) of the restricted stock unit award will vest on the one (1) year anniversary of the date of grant, and the remaining seventy-five percent (75%) of the restricted stock unit award will vest on a monthly pro-rata basis over the remaining vesting period. Read SEC document |
| January 31, 2019 Filed Feb 4, 2019 16:07 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | GrantStock Options · Derivative | 138,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-005522 · a4.xml · derivative · entry 1 Sender Gary · CIK 0001659085 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,200 Underlying: Ordinary Shares · 138,200 shares Expires 2029-01-31 F1 · derivative.exercise_price: The exercise price is $1.90 per share. F2 · derivative.exercise_date: This option was granted on January 31, 2019. Vesting began on January 31, 2019 and ends on January 31, 2023. Twenty-five percent (25%) of the option award will vest on the one (1) year anniversary of the date of grant, and the remaining seventy-five percent (75%) of the option award will vest on a monthly pro-rata basis over the remaining vesting period. Read SEC document |
| May 23, 2018 Filed May 23, 2018 20:38 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | PurchaseOrdinary Shares | 2,000 | $4.57 | $9,140.00 |
DisclosureSEC source: 0001104659-18-035539 · a4.xml · nonDerivative · entry 1 Sender Gary · CIK 0001659085 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,200 Read SEC document |
| January 31, 2018 Filed Feb 2, 2018 16:11 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | GrantRestricted Stock Units · Derivative | 22,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-006234 · a4.xml · derivative · entry 2 Sender Gary · CIK 0001659085 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Ordinary Shares · 22,500 shares Expires 2021-01-31 F3 · derivative.exercise_price: The restricted stock units shall convert into ordinary shares on a one-for-one basis upon vesting of the units. F4 · derivative.exercise_date: Vesting of the restricted stock unit award is subject to U.S. Food and Drug Administration ("FDA") approval of a new drug application ("NDA") for lefamulin. Fifty percent (50%) of the restricted stock unit award will vest upon FDA approval of an NDA for lefamulin, and the remaining fifty percent (50%) of the restricted stock unit award will vest on the one (1) year anniversary of such approval. If the FDA does not approve an NDA for lefamulin within two years of the grant date, the the restricted stock unit award will terminate in full. Read SEC document |
| January 31, 2018 Filed Feb 2, 2018 16:11 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | GrantStock Options · Derivative | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-006234 · a4.xml · derivative · entry 1 Sender Gary · CIK 0001659085 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Ordinary Shares · 100,000 shares Expires 2028-01-31 F1 · derivative.exercise_price: The exercise price is $6.47 per share. F2 · derivative.exercise_date: The option award was granted on January 31, 2018. Vesting began on January 31, 2018 and ends on January 31, 2022. Twenty-five percent (25%) of the option award will vest on the one (1) year anniversary of the date of grant, and the remaining seventy-five percent (75%) of the option award will vest on a monthly pro-rata basis over the remaining vesting period. Read SEC document |
| September 22, 2017 Filed Sep 26, 2017 17:01 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | PurchaseOrdinary Shares | 2,000 | $8.21 | $16,420.00 |
DisclosureSEC source: 0001104659-17-058897 · a4.xml · nonDerivative · entry 1 Sender Gary · CIK 0001659085 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,200 Read SEC document |
| June 23, 2017 Filed Jun 28, 2017 10:01 UTC | Nabriva Therapeutics Legacy plc NBRV · Entity 174291 | OtherStock Option · Derivative | 113,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-041909 · a4.xml · derivative · entry 3 Sender Gary · CIK 0001659085 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,000 Underlying: Ordinary Shares · 113,000 shares Expires 2027-02-06 F4 · derivative.exercise_price: The exercise price is 7.963 Euro. F1 · kind: Reflects the beneficial ownership of the reporting person following the succession pursuant to Rule 12g-3(a) of the Securities Exchange Act of 1934, as amended, of Nabriva Therapeutics plc to Nabriva Therapeutics AG. The succession occurred following the conclusion, on June 23, 2017, of a tender offer related to the exchange of American depositary shares and common shares of Nabriva Therapeutics AG for ordinary shares of Nabriva Therapeutics plc. F5 · derivative.exercise_date: This option was granted on February 7, 2017. Vesting began on February 28, 2017 and will end on February 28, 2021. Twenty-five percent (25%) of the option will vest on February 28, 2018, and the remaining seventy-five percent (75%) will vest on a monthly pro-rata basis over the remaining vesting period. Read SEC document |
| June 23, 2017 Filed Jun 28, 2017 10:01 UTC | Nabriva Therapeutics Legacy plc NBRV · Entity 174291 | OtherStock Option · Derivative | 88,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-041909 · a4.xml · derivative · entry 2 Sender Gary · CIK 0001659085 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,800 Underlying: Ordinary Shares · 88,800 shares Expires 2026-05-30 F2 · derivative.exercise_price: The exercise price is 6.50 Euro. F1 · kind: Reflects the beneficial ownership of the reporting person following the succession pursuant to Rule 12g-3(a) of the Securities Exchange Act of 1934, as amended, of Nabriva Therapeutics plc to Nabriva Therapeutics AG. The succession occurred following the conclusion, on June 23, 2017, of a tender offer related to the exchange of American depositary shares and common shares of Nabriva Therapeutics AG for ordinary shares of Nabriva Therapeutics plc. F3 · derivative.exercise_date: This option was granted on May 31, 2016. Vesting began on May 31, 2016 and ends on May 31, 2020. Twenty-five percent (25%) of the option will vest on May 31, 2017, and the remaining seventy-five percent (75%) vests on a monthly pro-rata basis over the remaining vesting period. Read SEC document |
| June 23, 2017 Filed Jun 28, 2017 10:01 UTC | Nabriva Therapeutics Legacy plc NBRV · Entity 174291 | OtherOrdinary Shares | 2,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-041909 · a4.xml · nonDerivative · entry 1 Sender Gary · CIK 0001659085 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,200 F1 · kind: Reflects the beneficial ownership of the reporting person following the succession pursuant to Rule 12g-3(a) of the Securities Exchange Act of 1934, as amended, of Nabriva Therapeutics plc to Nabriva Therapeutics AG. The succession occurred following the conclusion, on June 23, 2017, of a tender offer related to the exchange of American depositary shares and common shares of Nabriva Therapeutics AG for ordinary shares of Nabriva Therapeutics plc. Read SEC document |
| February 07, 2017 Filed Feb 9, 2017 16:35 UTC | Nabriva Therapeutics plc NBRV · Entity 111497 | GrantStock Option · Derivative | 11,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-007831 · a4.xml · derivative · entry 1 Sender Gary · CIK 0001659085 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,300 Underlying: Common Shares · 11,300 shares Expires 2027-02-06 F1 · derivative.exercise_price: The exercise price is 79.63 Euro. F2 · derivative.exercise_date: This option was granted on February 7, 2017. Vesting will begin on February 28, 2017 and end on February 28, 2021. Twenty-five percent (25%) of the option will vest on February 28, 2018, and the remaining seventy-five percent (75%) will vest on a monthly pro-rata basis over the remaining vesting period. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.